ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

New publication addresses IV therapy silent threat, identifies ivWatch as ‘transformative tool’ in NICU patient care

VieCure Expands Precision Oncology Ecosystem Through Strategic Partnership with Guardant Health

VieCure announced a strategic partnership with Guardant Health to embed Guardant’s next-generation sequencing-based precision oncology tests into the VieCure Halo Intelligence platform.

PubHive Wins Award for Innovative Literature Review Software

PubHive wins GHP's 2025 award for Most Innovative Literature Review Software, redefining life science workflows with AI-powered automation.

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025.

ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test. The UKCA mark, established as part of the United Kingdom’s independent product safety regulatory framework following its departure from the European Union, signifies compliance with UK medical device regulations and paves the way for commercial availability in the UK market.

Cresset Acquires Molab.ai to Advance Digitization of Drug Discovery

July 8 2025 – Cambridge UK – Cresset, a leading provider of innovative solutions for the digitization of drug discovery, announces the acquisition of Molab.ai, a pioneer in artificial intelligence technologies tailored for molecular research. This strategic acquisition will combine Cresset’s powerful computational chemistry platform with Molab.ai’s proven capability to build highly predictive ADME models. It marks a significant step in Cresset’s mission to empower scientists with cutting-edge tools to accelerate drug discovery.

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Bio-Rad Laboratories today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology

SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows

SPT Labtech today announced a strategic collaboration with Semarion. The partnership will integrate SPT Labtech’s firefly® liquid handling platform with Semarion’s SemaCyte® microcarrier technology to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.

Spartanburg Regional Healthcare System (SRHS) Selects AccessDx Laboratory as Pharmacogenomics (PGx) Program Partner

CD Bioparticles Launches Purified Exosomes for Drug Delivery and Therapeutic Research

CD Bioparticles announces quality Purified Exosomes to support research in drug delivery.

Axplora announces further €35M expansion at Farmabios to double footprint and fuel long-term growth

PHARMASEAL and Viedoc Announce a Technical Integration Partnership

PHARMASEAL, provider of the Engility® Trial Management Platform consisting of a Clinical Trial Management System (CTMS) CTMS and Electronic Trial Master File (eTMF), has announced a Technology Integration Partnership with Viedoc, a global leader in Electronic Data Capture (EDC) and eClinical technologies. This collaboration integrates PHARMASEAL’s advanced CTMS platform with Viedoc’s cutting-edge EDC capabilities, including its flagship product Viedoc Clinic, to deliver a more integrated solution for life science companies managing clinical trials worldwide.

Optibrium Partners with TalTech on EU-Funded PhD Programme to Advance Sustainable Drug Discovery

The research will focus on developing faster and more accurate methods for predicting drug metabolism

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys has received regulatory approvals in Australia and New Zealand for its innovative infertility solutions—FemaSeed®, a first-line, intratubal insemination treatment, and FemVue®, a diagnostic tool for assessing fallopian tube patency. These approvals mark a strategic expansion of the company’s global footprint and further validate its mission to offer more accessible, less invasive, and cost-effective fertility care. With FemaSeed shown to more than double pregnancy rates over traditional IUI in clinical trials, and FemVue enabling real-time fertility diagnostics in-office, this milestone offers new hope to patients facing infertility and strengthens Femasys’ commercial potential in international markets.

ZeOmega and MedeAnalytics Unveil Joint Population Health Solution to Accelerate Value-Based Care

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

PharmaForceIQ Announces Substantial Growth as it Expands Optichannel Engagement Solutions

PharmaForceIQ has announced a period of significant growth as it goes beyond omnichannel to optichannel campaign solutions. The company is the fastest growing independent provider of precision customer engagement technologies for the Life Science industry, and it has experienced a multifold increase in average contract value in the past year. In one client, the company expanded from a pilot campaign for one specialty brand to their entire specialty pharmaceutical portfolio in only 7 months. PharmaForceIQ also has a 100% client renewal rate – demonstrating that its data-driven strategies deliver unmatched efficiency and tangible results

Dr Quin Wills Appointed as Ochre Bio CEO

Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.